Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Development of Lipid Nanoparticles for B-cell Mediated Immunotherapies

Award Number: K00CA274651
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 12/01/2024
PERIOD OF PERFORMANCE END DATE: 11/30/2028

Group Awards By:

View Award Description

Development of Lipid Nanoparticles for B-cell Mediated Immunotherapies - Gene therapy has had an exciting last decade with many novel FDA approved therapies reaching the clinic. These treatments have not only been fruitful in cancer treatment, but also for genetic diseases and, more recently, in COVID-19 vaccines. Unlike macromolecules or small molecules, nucleic acids (DNA or RNA) require an efficient engineered delivery vehicle for effective treatment owing to either their high negative charge or high degradation rate which hinder cellular entry and systemic circulation, respectively. Although challenging to deliver, nucleic acids have a highly modular payload given that, with similar biophysical properties, they can transcribe or translate into a wide range of products, making the way for a truly modular platform for therapeutic delivery. Compared to systemic macromolecule administration, the delivered nucleic acid cargo can promote local and long-lasting production of a target therapeutic such as a cytokine for immunotherapy. Further, many promising gene modulation approaches exist beyond the delivery of a gene for transcription or translation such as RNA interference, gene silencing, antisense therapy, and gene editing. Consistent with the goals of nanotechnology for cancer treatment provided by the NCI, this project will focus on designing and characterizing the stability of lipid nanoparticles (LNPs) to induce an anti-tumor immune response. The target immune response will be mediated by B cell responses via CMTR2 depletion, an exciting new pathway to induce anti-tumor immune responses. Combination strategies using CMTR2 depletion with other immunomodulatory treatments will also be explored to further enhance the B- cell responses.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $80,231 )
2026	2026	BRIGHAM & WOMENS HOSPITAL INC	75 FRANCIS ST	BOSTON	MA	02115	SUFFOLK	USA	Cancer Research Manpower	000	4	12/10/2025	NON-COMPETING CONTINUATION	$80,231
														Subtotal = $80,231

Issue Date FY: 2025 ( Subtotal = $90,765 )
2025	2025	BRIGHAM & WOMENS HOSPITAL INC	75 FRANCIS ST	BOSTON	MA	02115	SUFFOLK	USA	Cancer Research Manpower	000	3	1/14/2025	EXTENSION WITH OR WITHOUT FUNDS	$90,765
														Subtotal = $90,765

Grand Total All Awards = $170,996

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of Lipid Nanoparticles for B-cell Mediated Immunotherapies

Award Number: K00CA274651

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 12/01/2024

PERIOD OF PERFORMANCE END DATE: 11/30/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer